---
layout: minimal-medicine
title: Coagulation Factor VIIa Recombinant
---

# Coagulation Factor VIIa Recombinant
### Generic Name
Coagulation Factor VIIa Recombinant

### Usage

Coagulation Factor VIIa recombinant is a crucial medication used to manage and treat bleeding episodes in various conditions. Its primary application is in individuals with hemophilia A or B who have developed inhibitors (antibodies that neutralize standard clotting factor replacement therapies).  It's also indicated for those with congenital Factor VII deficiency (a rare inherited bleeding disorder) and Glanzmann thrombasthenia (a platelet disorder) that doesn't respond to platelet transfusions.  Additionally, it finds use in adults with acquired hemophilia (a condition where the body doesn't produce enough clotting factors).  Perioperative management (before, during, and after surgery) is another significant application across these conditions to prevent and control bleeding.  Note that specific indications and uses may vary depending on the specific brand and formulation of the medication.

### Dosage

Dosage for Coagulation Factor VIIa recombinant is highly individualized and depends on several factors, including the patient's weight, age, specific condition, severity of bleeding, and response to treatment.  It's crucial to follow the prescribing healthcare professional's instructions meticulously.  The following information provides general guidelines only and should not be interpreted as a substitute for professional medical advice:


**Adults:** Dosages typically range from 15-90 mcg/kg (micrograms per kilogram of body weight), administered intravenously (IV).  The frequency of administration also varies, ranging from every 2-6 hours, depending on the condition and the bleeding's severity.  For instance, in acquired hemophilia, a dosage of 70-90 mcg/kg every 2-3 hours might be used for bleeding episodes, while perioperative management may involve the same dosage before surgery and then repeated at 2-3 hour intervals throughout the procedure. In congenital factor VII deficiency, lower doses (15-30 mcg/kg) might be sufficient, administered every 4-6 hours.

**Children:** Dosage and administration frequency for children are also determined on a case-by-case basis, typically adjusting for body weight and specific needs.  In children with hemophilia A or B with inhibitors, the dose is often 90 mcg/kg every 2 hours for bleeding episodes, with similar adjustments for perioperative management as in adults. For congenital factor VII deficiency in children, lower doses are typically used, similar to the adult regimen.

**Specific conditions and variations:** The dosage and frequency significantly vary based on the specific condition being treated (hemophilia A/B with inhibitors, congenital factor VII deficiency, Glanzmann thrombasthenia, acquired hemophilia) and whether it's for a bleeding episode or perioperative management. Always adhere to the prescribed dosage regimen.


### Side Effects

The side effects of Coagulation Factor VIIa recombinant can range from mild to severe.  The likelihood of experiencing specific side effects also varies based on several factors.

**Common side effects:**

* Headache
* Dizziness
* Injection site reactions (pain, redness, swelling)
* Increased blood pressure (hypertension)

**Less common, but serious side effects:**

* Thrombosis (blood clots) in arteries or veins (deep vein thrombosis, pulmonary embolism, stroke, heart attack)
* Allergic reactions (ranging from mild rash to severe anaphylaxis)
* Decreased fibrinogen levels (a clotting protein)

**Important Note:** If any side effects occur, especially those that are severe or unusual, consult a healthcare provider immediately.


### How it Works

Coagulation Factor VIIa recombinant is a synthetic version of a naturally occurring protein involved in blood clotting.  It works by activating the extrinsic pathway of the coagulation cascade â€“ a series of reactions that lead to the formation of a blood clot.  Specifically, it activates factors X and IX, which ultimately contribute to the conversion of prothrombin to thrombin, a crucial step in clot formation.  Essentially, it bypasses some of the usual clotting factor deficiencies and helps to form a stable clot to stop bleeding.  This mechanism of action is particularly helpful in individuals who have inhibitors to the standard clotting factors.


### Precautions

* **Thrombosis:**  A significant risk associated with Coagulation Factor VIIa recombinant is the development of blood clots (thrombosis).  This risk is increased in certain individuals, and close monitoring is essential.
* **Hypersensitivity:** Allergic reactions are possible.  Patients with known allergies to components of the medication should use caution.
* **Drug interactions:**  Coagulation Factor VIIa recombinant may interact with other medications, particularly those that affect blood clotting. Discuss any other medications you are taking with your doctor or pharmacist.
* **Pregnancy and breastfeeding:** Use during pregnancy should be carefully considered and only if the benefits outweigh the potential risks to the fetus. The safety during breastfeeding isn't fully established.
* **Hepatic and renal impairment:** Individuals with liver or kidney problems may require dosage adjustments or careful monitoring.
* **Older adults and children:**  Dosage adjustments may be necessary for older adults and children.

**Contraindications:** Coagulation Factor VIIa recombinant is contraindicated in patients with severe hypersensitivity to it or its components.


### FAQs

* **Q: How long does it take for Coagulation Factor VIIa recombinant to work?**
    * A: The onset of action can vary depending on the individual and the specific situation, but it generally starts working relatively quickly.

* **Q: How is Coagulation Factor VIIa recombinant stored?**
    * A: Specific storage instructions will be provided on the product labeling. Generally, it needs to be refrigerated.

* **Q: Can I take Coagulation Factor VIIa recombinant with other medications?**
    * A: It's essential to inform your healthcare provider of all medications you're currently taking to avoid potential interactions.

* **Q: Are there long-term effects associated with Coagulation Factor VIIa recombinant use?**
    * A: Long-term effects are less studied compared to shorter-term effects,  and the potential for long-term effects will vary depending on the frequency and duration of treatment. Regular monitoring by a healthcare professional is necessary.

* **Q: What should I do if I miss a dose?**
    * A: Contact your doctor or pharmacist immediately for guidance.  Do not attempt to double up on doses.

**Disclaimer:** This information is intended for educational purposes only and should not be considered medical advice.  Always consult with a healthcare professional for any health concerns or before making any decisions related to your health or treatment.  This information may not encompass all aspects of Coagulation Factor VIIa recombinant's use and potential side effects.
